EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Austrian treatment algorithms 2025: CDK 4/6 inhibitors in the adjuvant therapy of HR+/HER2− early breast cancer

Rupert Bartsch, Clemens Dormann, Daniel Egle, Simon P Gampenrieder, Gunda Pristauz-Telsnigg, Gabriel Rinnerthaler, Christian F Singer, Michael Gnant

Wiener klinische Wochenschrift · 2026-10 · 138 (19-20) · 599-611

DOI: 10.1007/s00508-026-02726-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Wiener klinische Wochenschrift, online erschienen am 18.03.2026. Verfasst von Rupert Bartsch und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Algorithms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) early breast cancer (eBC) represents the most common breast cancer subtype, with relevant recurrence risks despite optimal endocrine therapy (ET) and locoregional treatment. Long-term data from the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) demonstrate that recurrence risk remains substantial, with outcomes strongly influenced by nodal burden, tumor size, and biological parameters. Advances in systemic therapy, including optimized endocrine strategies, chemotherapy, bone-modifying agents, PARP inhibitors for patients harboring germline BRCA 1/2 -mutations, have significantly improved survival, yet recurrence remains a clinically relevant challenge, including for node-negative patients harboring additional biological risk features. The introduction of adjuvant CDK4/6 inhibitors represents an important therapeutic development. Abemaciclib (monarchE) has demonstrated sustained improvements in invasive disease-free survival (IDFS), distant relapse-free survival (DRFS), and a statistically significant overall survival (OS) benefit at 7 years. Ribociclib (NATALEE) demonstrated statistically significant IDFS improvement across a broader clinical risk spectrum, including selected node-negative disease. However, these advances must be considered in the context of distinct toxicity, treatment burden, and substantial additional healthcare system costs. Although emerging evidence supports treatment intensification with CDK4/6 inhibitors in certain settings, uncertainty persists regarding which patient subgroups derive sufficient benefit to justify routine use from both a clinical and health-economic perspective. Further clarification is expected from ongoing randomized studies and real-world evidence, as this paper aims to provide a structured, evidence-based overview of the current standard of knowledge and to support Austrian breast cancer specialists in navigating treatment decisions regarding adjuvant CDK4/6 inhibitor use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6AlgorithmsHumansFemaleChemotherapy, AdjuvantBenzimidazolesAminopyridinesErb-b2 Receptor Tyrosine KinasesNeoplasm Recurrence, LocalReceptors, ProgesteroneReceptors, EstrogenDisease-Free SurvivalPurines

Stichwörter der Autor:innen

Abemaciclib, RibociclibAdjuvant therapyBreast cancerCDK4/6 inhibitorsRecurrence risk of luminal breast cancer

Substanzen

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6BenzimidazolesAminopyridinesErb-b2 Receptor Tyrosine KinasesabemaciclibCDK6 protein, humanCDK4 protein, humanERBB2 protein, humanReceptors, Progesterone

Autor:innen und Institutionen

  • Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Department of Internal Medicine, Medical Oncology and Hematology, Ordensklinikum Linz-Barmherzige Schwestern, Linz, Austria.
  • Department of Obstetrics and Gynecology, Breast Cancer Unit, Medical University of Innsbruck, Innsbruck, Austria.
  • Department of Internal Medicine III, Division of Hematology, Medical Oncology, Hemostaseology and Infectious Diseases, Paracelsus Medical University Salzburg, Salzburg, Austria.
  • Landeskrankenhaus Oststeiermark, Standort Feldbach, Department of Obstetrics and Gynecology, Feldbach, Styria, Austria.
  • Clinical Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Förderung

  • Medical University of Vienna

Zitieren

APA

Bartsch, R., Dormann, C., Egle, D., Gampenrieder, S. P., Pristauz-Telsnigg, G., Rinnerthaler, G., Singer, C. F., & Gnant, M. (2026). Austrian treatment algorithms 2025: CDK 4/6 inhibitors in the adjuvant therapy of HR+/HER2− early breast cancer. Wiener klinische Wochenschrift, 138(19-20), 599-611. https://doi.org/10.1007/s00508-026-02726-8

Vancouver

Bartsch R, Dormann C, Egle D, Gampenrieder SP, Pristauz-Telsnigg G, Rinnerthaler G, et al. Austrian treatment algorithms 2025: CDK 4/6 inhibitors in the adjuvant therapy of HR+/HER2− early breast cancer. Wiener klinische Wochenschrift. 2026;138(19-20):599-611. doi:10.1007/s00508-026-02726-8

BibTeX
@article{Bartsch2026,
  author = {Bartsch, Rupert and Dormann, Clemens and Egle, Daniel and Gampenrieder, Simon P and Pristauz-Telsnigg, Gunda and Rinnerthaler, Gabriel and Singer, Christian F and Gnant, Michael},
  title = {Austrian treatment algorithms 2025: CDK 4/6 inhibitors in the adjuvant therapy of HR+/HER2− early breast cancer},
  journal = {Wiener klinische Wochenschrift},
  year = {2026},
  volume = {138},
  number = {19-20},
  pages = {599--611},
  doi = {10.1007/s00508-026-02726-8}
}
Kostenlos starten →